Across TCGA pan-cancer cohorts, TAF8 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TAF8 data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher TAF8 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TAF8 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
KIRP, THCA, and UCEC are the cancer types where TAF8 Mutation most reproducibly stratifies survival.